

vedolizumab (ENTYVIO) – Maintenance Only
Infusion Therapy Plan Orders

Page 1 of 3

Name: _____

Kaiser Permanente Member I.D. #: _____

Date of Birth: _____

Instructions to Provider

Review orders and note any changes. All orders with ☒ will be placed unless otherwise noted. Please fax completed order form to the infusion center where the patient will be receiving treatment (see fax numbers using the link at the end of this protocol).

Lab orders are not included on this form – place orders via usual method. Lab monitoring is the responsibility of the ordering physician.

Please complete all the following:

Order Date: _____

Weight: _____ kg

Diagnosis

ICD-10 code (REQUIRED): _____

ICD-10 description: _____

General Plan Communication

- Discontinue therapy if no evidence of therapeutic benefit by week 14
- Special instructions/notes:**

Provider Information

- Treatment with vedolizumab not recommended in patients with active, severe infections. Consider withholding vedolizumab in patients who develop a severe infection while on treatment.
- Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy.
- Risk of developing Progressive Multifocal Leukoencephalopathy (PML): Monitor for new or worsening neurological signs or symptoms.
- Monitor for signs and symptoms of liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.

Infusion Therapy☒ **vedolizumab (ENTYVIO) 300 mg in 0.9% sodium chloride 250 mL IV infusion****Dose:** ☐ 300 mg**Route:** Intravenous**Frequency:** Every 8 weeks**Infusion Rate:** Infuse over 30 minutes, starting 60 minutes after treatment start time**If infusion-related reaction:**

- 1) STOP infusion immediately
- 2) Begin primary infusion to wide open rate
- 3) Notify MD
- 4) Monitor vital signs
- 5) Administer PRN medications
- 6) 30 minutes after symptoms have resolved, restart infusion at 50% of rate when reaction occurred

Note any changes to above regimen:
_____**Pre-Medications**☒ **acetaminophen (TYLENOL) tablet****Dose:** 650 mg **Route:** Oral**Frequency:** Once PRN, 30 minutes prior to vedolizumab infusion if patient has history of prior reaction. May also be given once as needed during infusion for achiness, headache, or fever☒ **cetirizine (ZYRTEC) tablet****Dose:** 10 mg **Route:** Oral**Frequency:** Once PRN, 30 minutes prior to vedolizumab infusion (if not taken at home) if patient has history of prior reaction**Provider Signature:** _____ **Date:** _____**Printed Name:** _____ **Phone:** _____ **Fax:** _____

vedolizumab (ENTYVIO) – Maintenance Only

Infusion Therapy Plan Orders

Page 2 of 3

Name: _____
Kaiser Permanente Member I.D. #: _____
Date of Birth: _____

<input checked="" type="checkbox"/>	Other: _____	Dose: _____	Route: _____	Frequency: Once PRN, 30 minutes prior to vedolizumab infusion
IV Line Care				
<input checked="" type="checkbox"/>	0.9% Saline (NS) infusion 250 mL	Rate: 30 mL/hr	Route: Intravenous	Frequency: Run continuously to keep vein open. Start peripheral IV if no central line
PRN & Hypersensitivity Reaction Medications				
<input checked="" type="checkbox"/>	ondansetron (ZOFRAN) (PF) Injection	Dose: 8 mg	Route: Intravenous	Frequency: Give IV push one time PRN for nausea or vomiting.
<input checked="" type="checkbox"/>	acetaminophen (TYLENOL) tablet	Dose: 650 mg	Route: Oral	Frequency: Take 650 mg PO every 4 hours PRN for fever (greater than 100.4 F), myalgias, arthralgias or headache.
<input checked="" type="checkbox"/>	alteplase (CATHFLO ACTIVASE) injection	Dose: 2 mg	Route: Intracatheter	Frequency: Instill 2 mg to affected port(s) of central venous catheter if sluggish or occluded. Allow to dwell for 30 minutes, if unable to aspirate blood allow to dwell for an additional 90 minutes. May repeat one time if unsuccessful.
<input checked="" type="checkbox"/>	diphenhydrAMINE (BENADRYL) injectable	Dose: 50 mg	Route: Intravenous	Frequency: Once PRN for urticaria, pruritus, shortness of breath. May repeat one time in 15 minutes if symptoms not resolved. Notify MD upon giving medication
<input checked="" type="checkbox"/>	famotidine (PEPCID) (PF) injection	Dose: 20 mg	Route: Intravenous	Frequency: Give IV push over 2 minutes for hives, rash, itching, flushing, and/or swelling in a suspected hypersensitivity reaction. Give immediately after diphenhydrAMINE. Notify provider if patient experiences a hypersensitivity reaction.
<input checked="" type="checkbox"/>	methyIPREDNISolone Sod Succ (PF) Inj 125 mg (SOLU-Medrol PF)	Dose: 125 mg	Route: Intravenous	Frequency: Give 125 mg IV push one time PRN for shortness of breath, bronchospasm, or other symptoms of a suspected hypersensitivity reaction not otherwise specified. Notify provider if patient experiences a hypersensitivity reaction.
<input checked="" type="checkbox"/>	sodium Chloride 0.9% IV bolus	Dose: 1000 mL	Route: Intravenous	Frequency: Give IV over 1 hour one time PRN for hypotension due to presumed anaphylaxis. Notify provider if patient experiences a hypersensitivity reaction.
<input checked="" type="checkbox"/>	EPINEPHrine (Epi-Pen) 0.3 mg/0.3 mL IM Auto-Injector	Dose: 0.3 mg	Route: Intramuscular	Frequency: Once PRN for anaphylaxis. Give IM one time for severe cardiovascular or respiratory symptoms (e.g. dyspnea, wheeze/bronchospasm, stridor, hypoxemia) of a suspected hypersensitivity reaction. Provider must be present upon given medication.
Nursing Orders				
<ul style="list-style-type: none"> • Ensure CBC, AST and ALT, and Creatinine have been drawn within the last 16 weeks. • If labs have not been drawn within 16 weeks, proceed with infusion and instruct patient to receive lab draw today. • Notify provider if patient is more than 20 weeks overdue for labs. • Monitor for temperature greater than 100.4F, chills, pruritus, chest pain, blood pressure changes (notify MD if greater than 10% drop in systolic blood pressure or if patient is symptomatic), or dyspnea. • For hypersensitivity: stop vedolizumab, give diphenhydramine and steroid as ordered. 				

Provider Signature: _____ Date: _____

Printed Name: _____ Phone: _____ Fax: _____

**vedolizumab (ENTYVIO) – Maintenance Only
Infusion Therapy Plan Orders**

Page 3 of 3

Name: _____

Kaiser Permanente Member I.D. #: _____

Date of Birth: _____

- Review discharge medications, instructions, and future appointments.

References

vedolizumab® (ENTYVIO) injection for subcutaneous or intravenous use Prescribing Information. Revised April 2024.

Kaiser Permanente Infusion Locations

Please refer to the link below for the current list and contact information:

<https://wa-provider.kaiserpermanente.org/patient-services/ambulatory-infusion>

Provider Signature: _____ Date: _____

Printed Name: _____ Phone: _____ Fax: _____